Phaseline

Targets › MUC5AC

MUC5AC (Mucin-5AC): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Respiratory; next expected readout Dec 2027.

Gel-forming glycoprotein of gastric and respiratory tract epithelia that protects the mucosa from infection and chemical damage by binding to inhaled microorganisms and particles that are subsequently removed by the mucociliary system. Interacts with H.pylori in the gastric epithelium, Barrett's esophagus as well as in gastric metaplasia of the duodenum (GMD). (UniProt, P98088)

Open in Phaseline: the race on MUC5AC, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Institute of Environmental Health Sciences (NIEHS)hymecromone
Mucin secretion inhibitor; reduces excessive mucus production in airways
MUC5ACPhase 2Interstitial Lung DiseaseDec 2027

Conditions

Interstitial Lung Disease (1)

Modalities

small molecule (1)

Companies

National Institute of Environmental Health Sciences (NIEHS) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.